| abstract |
The use of a COX-2 inhibitor of general formula B: in which Y represents a cyclic group, preferably an oxazolyl, isoxazolyl, thienyl, dihydrofuryl, furyl, pyrrolyl, pyrazolyl, thiazolyl, imidazolyl, isothiazolyl, cyclopentenyl, phenyl or pyridyl ; n is an integer from 0 to 3; m is an integer from 0 to 4; R6 represents a ketocyclyl, cycloalkyl or aryl group, and said group may be optionally substituted with one or more groups or atoms, preferably with one or more halogen atoms; R7 each independently represents a substituent that may be any functional group, preferably a hydrogen or halogen atom, or an alkyl group, and said alkyl group may be substituted with one or more groups or atoms; R8 represents an alkyl or NHR10 group; R9 represents a halogen atom; and R10 represents a hydrogen atom or an alkyl group optionally substituted with one or more groups or atoms, preferably with an acyl group; or a pharmaceutically acceptable salt thereof in the preparation of a medicament for mitigating the dysfunction of T cells in a human with HIV or AIDS, in which said medicament is formulated for oral administration. |